Screener
Cogent Biosciences, Inc. COGT Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Property and equipment, net | 5,298 | 5,457 |
| Restricted cash | 416 | 416 |
| Other assets | 1,940 | 3,301 |
| Total assets | $903,006 | $937,607 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $13,744 | $9,504 |
| Accrued expenses and other current liabilities | 42,854 | 52,902 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Cogent Biosciences, Inc.'s total assets?
- Cogent Biosciences, Inc. (COGT) reported total assets of $903.01M in Q1 2026.
- How has Cogent Biosciences, Inc.'s total assets changed year-over-year?
- Cogent Biosciences, Inc.'s total assets increased by 218.2% year-over-year, from $283.8M to $903.01M.
- What is the long-term trend for Cogent Biosciences, Inc.'s total assets?
- Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s total assets has grown at a 30.2% compound annual growth rate (CAGR), from $250.92M to $937.61M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Cogent Biosciences, Inc.'s total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude